Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
Open Access
- 7 July 2020
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 9 (7) , 388
Abstract
Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until 12 February 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies published in peer-reviewed journals and in the English language. The primary outcome was all-cause mortality (longest follow-up) evaluated in patients with the diagnosis of infection with at least one pathogen; secondary outcomes were clinical and microbiological improvement/cure. Thirteen studies were included in the qualitative synthesis: 7 RCTs and 6 retrospective studies All the six retrospective studies identified carbapenamase-producing Enterobacteriaceae (CRE) as the cause of infection and for this reason were included in the network meta-analysis (NMA); the quality of the studies, assessed using the New Castle-Ottawa Scale, was moderate-high. In all the six retrospective studies included in the NMA, CZA was used in large part for off-label indications (mostly blood stream infections: 80–100% of patients included). No difference in mortality rate was observed in patients undergoing CZA combination therapy compared to CZA monotherapy [n = 503 patients, direct evidence OR: 0.96, 95% CI: 0.65–1.41].Keywords
This publication has 32 references indexed in Scilit:
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 studyThe Lancet Infectious Diseases, 2016
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 ProgramClinical Infectious Diseases, 2016
- First outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Constantine, AlgeriaInternational Journal of Antimicrobial Agents, 2015
- Correction: Network Meta-Analysis Using R: A Review of Currently Available Automated PackagesPLOS ONE, 2015
- Network Meta-Analysis Using R: A Review of Currently Available Automated PackagesPLOS ONE, 2014
- Visualizing the flow of evidence in network meta‐analysis and characterizing mixed treatment comparisonsStatistics in Medicine, 2013
- A graphical tool for locating inconsistency in network meta-analysesBMC Medical Research Methodology, 2013
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trialJournal of Antimicrobial Chemotherapy, 2013
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurrent Medical Research and Opinion, 2012
- Combating Antimicrobial Resistance: Policy Recommendations to Save LivesClinical Infectious Diseases, 2011